Industry / United Kingdom
NICE Delivers Kidney Blow To Cancer Patients With New Guidelines
August 2008 | Industry NewsOnce again the National Institute for Health and Clinical Excellence (NICE) has hit the headlines in the UK, after preliminary guidance for kidney cancer treatment found that four expensive new drugs were not cost effective and as such would not be recommended for use. While the drugs - Roche's Avastin (bevacizumab), Bayer's Nexavar (sorafenib), Pfizer's Sutent (sunitinib) and Wyeth's Torisel (temsiromilus) - could extend advanced/metastatic kidney cancer patients' lives by several months, this was deemed at too high a cost for the National Health Service
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
